Fazarabine: a report of response in a patient with multiply relapsed embryonal cell carcinoma.

Abstract

This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy. The antimetabolic Ara-AC is worthy of further study in patients with germ-cell tumors. It would appear that the antimetabolite Ara-AC may have significant activity in patients with germ-cell tumors.

• Authors: P G Johnston, D Kleiner, K H Cowan
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 16 Issue 1 Pg. 34-7 (Feb 1993) ISSN: 0277-3732 [Print] United States
• PMID: 7678714 (Publication Type: Case Reports, Clinical Trial, Clinical Trial, Phase I, Journal Article)

Chemical References

• Antineoplastic Agents
• fazarabine
• Azacitidine

Topics

• Adult
• Antineoplastic Agents (therapeutic use)
• Azacitidine (therapeutic use)
• Humans
• Male
• Neoplasms, Germ Cell and Embryonal (drug therapy, secondary)